Persil Universal 4-in-1 Discs 132 (3 x 44) Wash Loads, Full Detergent with Deep Pur-Plus Technology and Long-lasting Freshness, Detergent for Bright Colours

Product Information

Discussion Paper on the impact on the volatility of own funds of the revised IAS 19 and the deduction of defined pension assets from own funds Articles 1 and 3 to 6 of Chapter 3 of the Liquidity Coverage Ratio (CRR) Part correspond to the articles of Commission Delegated Regulation (EU) 2016/709 with the same article number By way of derogation from point (a) of the first subparagraph of this paragraph, multilateral and bilateral development banks and other institutions that co-invest in a CIU with multilateral or bilateral development banks may determine the risk-weighted exposure amount of that CIU's exposures in accordance with the approaches set out in Article 132a, provided that the conditions set out in points (b) and (c) of the first subparagraph of this paragraph are met and that the CIU's investment mandate limits the types of assets that the CIU can invest in to assets that promote sustainable development in developing countries.

No corresponding rule for article 1(g) of Part 2 (PRA) of Commission Delegated Regulation (EU) 241/2014

Posters

Regulatory Technical Standards and Guidelines on estimation and identification of an economic downturn in IRB modelling Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities (UCITS) (OJ L 302, 17.11.2009, p. 32). Commission Implementing Regulation (EU) 2015/2344 of 15 December 2015 laying down implementing technical standards with regard to currencies with constraints on the availability of liquid assets in accordance with Regulation (EU) No 575/2013 of the European Parliament and of the Council. Articles 1 and 2 of Chapter 4 of the Liquidity Coverage Ratio (CRR) Part correspond to the articles of Commission Delegated Regulation (EU) 2017/208 with the same article number

Discussion paper on two delegated acts specifying further criteria for critical ICT third-party service providers (CTPPs) and determining oversight fees levied on such providers Extension of the application of the Joint Committee Guidelines on complaints-handling to the new institutions under PSD2 and MCD Council Regulation (EU) No 1024/2013 of 15 October 2013 conferring specific tasks on the European Central Bank concerning policies relating to the prudential supervision of credit institutions (OJ L 287, 29.10.2013, p. 63). Implementing Technical Standards on institutions’ public disclosures of the information referred to in Titles II and III of Part Eight of Regulation (EU) No 575/2013Immunogenic tumor tissues often have a high number of T cells, but their dysfunction limits their capacity to control tumors ( 13, 46). PD-1 + and TIM3 + TILs are considered to be terminally differentiated and dysfunctional TILs ( 44). Anti–PD-1/PD-L1 treatment can release the brake on the T cell response and partially restore their functions, but only a small number of patients have complete responses ( 9). Unexpectedly, we observed that IL-2 is required for optimal PD-1 therapy. This raises the possibility that targeting TILs with IL-2 might overcome PD-1 resistance. However, due to the high expression of IL-2 receptors on Treg cells, it is difficult to deliver enough IL-2 to CD8 + T cells in the tumor while avoiding systemic toxicity. Therefore, we designed a PD-1–laIL-2 fusion protein by linking low-affinity IL-2 to an anti–PD-1 antibody to target intratumoral PD-1–high CD8 + T cells instead of Tregs. PD-1–laIL-2 had much lower binding to peripheral CD8 + T cells and Treg cells, which greatly reduced peripheral consumption. A single low-dose of PD-1–laIL-2 treatment eradicated the tumors. PD-1–laIL-2 treatment favors CD8 + T cells over Treg cells in the tumor. Intriguingly, PD-1–laIL-2 could reactivate PD-1 +TIM3 +CD8 + TILs, and a long-term memory response was generated to protect against relapse. Overall, PD-1–laIL-2 is a next-generation PD-1 therapy that can target tumor-specific T cells. Article 272(5) (definition of “risk position” for the purposes of Chapter 6 of Title II of Part Three and Title VI of Part Three) of the CRR Regulatory Technical Standards on the procedure for the approval of white papers of ARTs issued by credit institutions